Stem cell technology for antitumor drug loading and delivery in oncology  

作　　者：FRANCESCO PETRELLA ENRICO MARIO CASSINA LIDIA LIBRETTI EMANUELE PIRONDINI FEDERICO RAVEGLIA ANTONIO TUORO 

机构地区：[1]Department of Thoracic Surgery,Fondazione IRCCSS an Gerardo dei Tintori,Monza,20900,Italy

出　　处：《Oncology Research》2024年第3期433-437,共5页肿瘤学研究（英文）

摘　　要：The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues,thus incrementing drug effects and,at the same time,reducing the damage of non-involved tissues to cytotoxic agents.Mesenchymal stromal cells(MSC)represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells.During the last year,they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cll,s thus optimizing cytotoxic action on cancer cll,while significantly reducing adverse side efect on healthy cells.MSC chemotherapeutic drug loading and delivery is an encouraging new area of cell therapy for several tumors,especially for those with unsatisfactory prognosis and limited treatment options available.Although some experim ental models have been sucesfuly developed,phase I dinical studies are needed to confirm this potential application of cell therapy,in particular in the case of primary and secondary lung cancers.

关 键 词：Mesenchymal stromal cell Drug loading Drug delivery MESOTHELIOMA Melanoma GLIOBLASTOMA Pancreatic ductal adenocarcinoma Multiple myeloma 

分 类 号：R730[医药卫生—肿瘤]